临时经静脉膈肌神经刺激用于机械通气脱机:RESCUE-3随机临床试验
RESCUE-3为国际多中心开放标签随机试验,纳入机械通气≥96小时、符合脱机标准且两次以上脱机失败的成人患者,比较每日两次经静脉膈肌神经刺激与标准治疗的脱机效果。因入组缓慢提前终止,改良意向治疗人群216例(治疗组102例,对照组114例)。第30天治疗组70%成功脱机,对照组61%,贝叶斯分析后验优势概率97.9%,但治疗组严重不良事件报告率36%高于对照组24%。
要点
- 经静脉膈肌神经刺激可能提高困难脱机患者的30天脱机成功率。
- 治疗组严重不良事件报告率36%高于对照组24%,需关注安全性。
- 试验因入组缓慢提前终止,结果需谨慎解读。
核心结论
- 尽管因入组缓慢提前终止,经静脉膈肌神经刺激在脱机成功方面显示出潜在获益的高概率,但严重不良事件可能增加。
研究设计与样本
- 国际多中心开放标签随机临床试验RESCUE-3,纳入机械通气≥96小时、符合脱机标准且两次以上脱机失败的成人患者。
- 因入组缓慢和资金考虑,在200例随机化后第一次中期分析时提前终止;改良意向治疗人群共216例(治疗组102例,对照组114例)。
- 主要结局为第30天成功脱机,预设主要分析采用贝叶斯方法,借用先前II期随机试验的先验信息并降权处理。
主要发现
- 第30天治疗组71例(70%)成功脱机,对照组69例(61%),调整风险比1.34(95%可信区间1.01-1.78),后验优势概率97.9%。
- 治疗缩短通气持续时间,调整差值-2.5天(95%可信区间-5.0至0.1),后验优势概率97.1%。
- 治疗组36%报告严重不良事件,对照组24%;治疗组9.8%死亡,对照组10.5%,调整风险比0.74(95%可信区间0.37-1.46),后验优势概率80.6%。
临床怎么用
- 对机械通气≥96小时且多次脱机失败的患者,经静脉膈肌神经刺激可能作为辅助脱机策略,但需权衡严重不良事件风险。
局限性
- 试验因入组缓慢提前终止,样本量有限。
- 开放标签设计可能引入偏倚。
- 主要分析借用先前试验先验信息并降权,可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Diaphragm dysfunction impedes weaning from mechanical ventilation. Transvenous diaphragm neurostimulation can increase diaphragm strength, but its impact on patient outcomes is uncertain. OBJECTIVES: To test the safety and effectiveness of transvenous diaphragm neurostimulation to increase successful weaning in patients with difficulty weaning from mechanical ventilation in comparison with standard of care. METHODS: This international, multicenter, open-label, randomized clinical trial (RESCUE-3) included adult patients requiring mechanical ventilation for ⩾96 hours who met readiness-to-wean criteria and failed two or more weaning attempts. Patients were randomized to twice-daily transvenous diaphragm neurostimulation (treatment) or standard of care (control). The primary outcome was successful weaning at Day 30. Secondary outcomes included duration of ventilation to Day 30 and mortality at Day 30. The prespecified primary analysis utilized a Bayesian approach with borrowing of prior information from a previous Phase-II randomized trial, downweighted to account for possible differences in trials. MEASUREMENTS AND MAIN RESULTS: Because of slow enrollment and financial considerations, the trial was halted at the first interim analysis after 200 patients were randomized. Overall, 216 patients were randomized in the modified intent-to-treat population (treatment group, n = 102; control group n = 114). At Day 30, 71 (70%) patients in the treatment group and 69 (61%) patients in the control group were successfully weaned (adjusted hazard ratio, 1.34; 95% credible interval = 1.01-1.78; posterior probability of superiority, 97.9%). Treatment reduced the duration of ventilation (adjusted difference, -2.5 d; 95% credible interval = -5.0 to 0.1; posterior probability of superiority, 97.1%). Serious adverse events were reported in 36% of patients in the treatment group and 24% of patients in the control group; 9.8% of patients in the treatment group and 10.5% of patients in the control group died (adjusted hazard ratio, 0.74; 95% credible interval = 0.37-1.46; posterior probability of superiority, 80.6%). CONCLUSIONS: Although the trial was stopped early because of slow enrollment, transvenous diaphragm neurostimulation showed a high probability of potential benefit for weaning success but with a possible increase in serious adverse events.
引用
- Dres M, Ewert R, Conrad SA, et al. Temporary Transvenous Diaphragm Neurostimulation for Weaning from Mechanical Ventilation (RESCUE-3): A Randomized Clinical Trial. Am J Respir Crit Care Med. 2026. PMID: 40498082. doi:10.1164/rccm.202505-1056OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。